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Abstract
Background: The combination of nivolumab, a programmed death-1 (PD-1) targeted monoclonal antibody, with
the cytotoxic T-lymphocyte antigen-4 (CTLA-4) targeted antibody, ipilimumab, represents a new standard of care in
the first-line setting for patients with intermediate- and poor-risk metastatic renal cell carcinoma (mRCC) based on
recent phase III data. Combining ipilimumab with nivolumab increases rates of grade 3 and 4 toxicity compared
with nivolumab alone, and the optimal scheduling of these agents when used together remains unknown. The aim
of the PRISM study is to assess whether less frequent dosing of ipilimumab (12-weekly versus 3-weekly), in combination
with nivolumab, is associated with a favourable toxicity profile without adversely impacting efficacy.
Methods: The PRISM trial is a UK-based, open label, multi-centre, phase II, randomised controlled trial. The trial
population consists of patients with untreated locally advanced or metastatic clear cell RCC, and aims to recruit
189 participants. Participants will be randomised on a 2:1 basis in favour of a modified schedule of 4 doses of 12-
weekly ipilimumab versus a standard schedule of 4 doses of 3-weekly ipilimumab, both in combination with
standard nivolumab. The proportion of participants experiencing a grade 3 or 4 adverse reaction within 12months
forms the primary endpoint of the study, but with 12-month progression free survival a key secondary endpoint. The
incidence of all adverse events, discontinuation rates, overall response rate, duration of response, overall survival rates
and health related quality of life will also be analysed as secondary endpoints. In addition, the potential of circulating
and tissue-based biomarkers as predictors of therapy response will be explored.
Discussion: The combination of nivolumab with ipilimumab is active in patients with mRCC. Modifying the frequency
of ipilimumab dosing may mitigate toxicity rates and positively impact quality of life without compromising efficacy, a
hypothesis being explored in other tumour types such as non-small cell lung cancer. The best way to give
this combination to patients with mRCC must be similarly established.
Trial registration: PRISM is registered with ISRCTN (reference ISRCTN95351638, 19/12/2017).
(Continued on next page)
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: N.Vasudev@leeds.ac.uk
†Hannah L. Buckley and Fiona J. Collinson are joint first author.
Sarah R. Brown and Naveen S. Vasudev are joint last author.
2Leeds Institute of Medical Research at St James’s, St. James’s University
Hospital, Beckett Street, Leeds LS9 7TF, UK
Full list of author information is available at the end of the article
Buckley et al. BMC Cancer         (2019) 19:1102 
https://doi.org/10.1186/s12885-019-6273-1
(Continued from previous page)
Trial status: At the time of submission, PRISM is open to recruitment and data collection is ongoing.
Keywords: Renal cancer, Nivolumab, Ipilimumab, Schedule, Safety, Efficacy, Randomised, Immunotherapy, Trial,
Background
Kidney cancer is the 14th most common cancer world-
wide with an estimated 400,000 new cases, and 175,000
attributable deaths, in 2018 [1]. The majority of kidney
cancers (90%) are renal cell carcinomas (RCC), most of
which (75%) are of the clear cell subtype [2].
For the past decade, the mainstay of treatment for pa-
tients with metastatic RCC (mRCC), has been in the form
of small molecule, vascular endothelial growth factor
receptor-targeted, tyrosine kinase inhibitors (VEGFR TKIs),
such as sunitinib and pazopanib. Whilst most patients ini-
tially get a clinical benefit from VEGFR TKIs, acquired re-
sistance is typically observed within months after starting
therapy, with median overall survival (OS) in the region of
2 years [3, 4]. The introduction of checkpoint inhibitors, tar-
geting the cytotoxic T-lymphocyte antigen 4 (CTLA-4) and
programmed death-1 (PD-1) T-cell receptors, has trans-
formed the treatment landscape for patients with mRCC.
The anti-PD1 antibody nivolumab, for example, is a stand-
ard treatment option following failure of VEGFR TKI [5].
Recently (during the set-up of PRISM), initial results
from the landmark phase III trial, CheckMate 214
(CM214) comparing nivolumab plus the anti-CTLA-4
antibody ipilimumab against standard of care sunitinib,
have been reported. In total, 1096 participants with un-
treated metastatic clear cell RCC were randomised 1:1 to
receive either sunitinib (50 mg 4 weeks on; 2 weeks off)
or combination immunotherapy using a schedule of
nivolumab 3mg/kg (N3) plus ipilimumab 1mg/kg (I1)
every 3 weeks for 4 doses, followed by nivolumab 3mg/
kg every 2 weeks until disease progression or toxicity
warranting treatment discontinuation [6]. Amongst the
77% of participants with intermediate- or poor-risk dis-
ease, as per International Metastatic Renal Cell Carcin-
oma Database Consortium (IMDC) criteria [7], median
OS was not reached in the N3 + I1 arm and was 26.0
months in the sunitinib arm (HR 0.63, p < 0.001), estab-
lishing the combination as a new standard of care for
the first-line treatment of patients with intermediate-
and poor-risk mRCC [8]. Efficacy amongst favourable-
risk participants formed an exploratory endpoint of the
study and suggests improved response rates and PFS
amongst sunitinib-treated patients, although these re-
sults should be interpreted with caution given the imma-
ture nature of the survival data and small sample size
(n = 249). The reported toxicity associated with N3 + I1
was, however, significant. The rate of grade 3 or 4
treatment-related adverse events (AE) was 46% and led
to treatment discontinuation in 22% of participants re-
ceiving the combination. In addition, high dose gluco-
corticoids (≥ 40mg prednisone per day) were required
in 35% of participants in order to manage immune-
related AEs [6]. Until recently this combination treat-
ment was not available in the UK, however it has gained
approval for use in England through the national Cancer
Drugs Fund in early April 2019 [9].
Study rationale
Whilst CM214 has established the superior efficacy of
combination nivolumab with ipilimumab over sunitinib in
patients with intermediate- and poor-risk mRCC, optimal
scheduling of these drugs has not been explored in this
disease area. Additionally, improving our current under-
standing of why some patients respond to immunotherapy
whilst many others derive no benefit is recognised as a re-
search priority and translational studies focusing on pre-
dictive biomarkers forms a further important exploratory
objective of the trial.
PRISM is a Phase II, open label, multi-centre, parallel
group, randomised controlled trial. Our trial was de-
signed before CM214 results were available and seeks to
establish whether less frequent scheduling of ipilimumab
is associated with improved tolerability in patients with
mRCC in comparison to the schedule used in CM214,
without adversely impacting activity (in comparison with
historic control data).
Studies in other cancer types demonstrate ipilimumab
dose and / or frequency can affect the toxicity and efficacy
of treatment. In advanced melanoma, for example, 10mg/
kg ipilimumab every 3 weeks for 4 doses was associated
with longer median OS but higher rates of grade 3 or 4
toxicity, in comparison to 3mg/kg dosing [10]. A recently
reported melanoma trial comparing I3 + N1 versus I1 +
N3 again showed a favourable toxicity profile associated
with a lower dose of ipilimumab, with no apparent differ-
ence in efficacy at a minimum follow-up of 12months
[11]. Varying doses and schedules of ipilimumab plus
nivolumab have also been examined amongst 8 cohorts
within the phase Ib CM012 study in patients with non-
small cell lung cancer, including nivolumab 3mg/kg q2W
plus ipilimumab 1mg/kg given either 6- (n = 39) or 12-
(n = 38) weekly [12]. The schedule N3 (2-weekly) + I1 (6-
weekly) was selected for phase III evaluation based on its
safety and efficacy profile [13]. Thus, formal investigation
of the scheduling of ipilimumab when given in combin-
ation with nivolumab in patients with mRCC is warranted.
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It was not feasible to design the study for an internal
comparison of efficacy given the phase II nature of the
trial and the required sample size for such a comparison.
As the trial was designed prior to CM214 results being
available, PRISM is powered to compare activity of the
modified schedule with historic sunitinib control data,
however ancillary analyses will explore results in relation
to CM214.
Methods
Trial objectives
Primary objective
The primary aim of the PRISM trial is to assess whether the
proposed alternative scheduling of ipilimumab (12-weekly),
when given in combination with nivolumab, warrants further
consideration based on safety and efficacy, as defined by the
proportion of participants experiencing a grade 3 or 4 ad-
verse reaction (AR) within 12months and 12-month
progression-free survival (PFS).
Secondary objectives
Secondary objectives include assessment in each treat-
ment arm of: incidence of adverse reactions; treatment
discontinuation rates; overall response rate; duration of
response; response rate post-progression (for those re-
ceiving treatment beyond progression); overall survival
rates; and health-related quality of life (HR-QoL).
Exploratory objectives
To explore circulating and tissue-based predictive bio-
markers of response to immunotherapy.
Trial design
The study protocol and this manuscript have been writ-
ten in accordance with standard protocol items: recom-
mendations for interventional trials (SPIRIT) guidelines
[14]. We have included a SPIRIT checklist as supple-
mentary material (Additional file 1: Table S1).
The PRISM trial is an open label, multi-centre, phase
II, randomised controlled trial to explore the efficacy
and safety of alternative reduced intensity scheduling of
ipilimumab, when given in combination with nivolumab
as first-line therapy, in patients with locally advanced or
metastatic RCC. The trial will recruit 189 participants
with individual randomisation on a 2:1 basis in favour of
the modified schedule (see Fig. 1). The two arms of the
trial are as follows (see Fig. 2):
 Arm A (modified schedule): 3 mg/kg nivolumab
plus 1 mg/kg of ipilimumab every 12 weeks for 4
doses with:
 2-weekly 240 mg flat dose single agent nivolumab
between the first and second combined doses,
and
 4-weekly single agent nivolumab between the
second and third, and third and fourth combined
doses
 Followed by 4-weekly 480 mg flat dose single
agent nivolumab following the fourth combin-
ation dose, until disease progression/unacceptable
toxicity/participant choice.
 Arm B (standard schedule): 3 mg/kg nivolumab
intravenously plus 1 mg/kg of ipilimumab every 3
weeks for 4 doses. Followed by 4-weekly 480 mg flat
dose single agent nivolumab following the fourth
combination dose, until disease progression/un-
acceptable toxicity/participant choice.
Participants may receive treatment beyond first Re-
sponse Evaluation Criteria In Solid Tumors (RECIST)
v1.1 [15] defined progression based on investigator-
assessed clinical benefit, tolerance of study drugs and
stable performance status, as a minority of patients
treated with immunotherapy may derive clinical benefit
despite initial evidence of progressive disease. Trial treat-
ment will be discontinued permanently upon documen-
tation of further progression defined as the presence of
any new lesion or an additional 10% increase in existing
tumour burden from time of initial progression. Treat-
ment will also be discontinued if treatment is delayed or
interrupted for more than 6 weeks.
Quality of life evaluation
It is thought that nivolumab plus 12-weekly ipilimumab
could be associated with favourable HR-QoL in com-
parison to standard 3-weekly dosing of ipilimumab. In
order to evaluate treatment tolerability and its impact
from a patient perspective, Patient-Reported Outcome
Measures (PROM) to evaluate both overall HR-QoL and
patient-reported AEs (physical symptoms of RCC and
side effects of the treatments) will be collected. The se-
verity and trajectory of AEs (symptoms or side-effects)
of both treatment schedules will be reported, allowing
comparison between clinician reported AEs (CTCAE
V5.0) and patient-reported AEs using PROMs [16]. The
primary outcome measure will be the summary score for
HR-QoL of European Organisation for Research and
Treatment of Cancer (EORTC) QLQ-C30. Secondary
descriptive outcomes will include EQ-5D-5L™, physical
symptoms of RCC (measured by Functional Assessment
of Cancer Therapy Kidney Symptom Index (FKSI-19))
and known side-effects of ipilimumab and nivolumab
measured by selected items from EORTC Quality of Life
Group item bank [17]. We propose to use the item bank
approach to cover expected toxicity of the investigational
treatments, as due to the rapid introduction of new tar-
geted cancer treatments there are no existing validated
instruments that will cover the full range of AEs and
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using well developed and validated items from the item
bank is a viable rapid alternative. PRO measures will be
collected at baseline, weeks 7 and 13, then 12-weekly.
The data collection will stop at disease progression or
61 weeks, whichever is earlier.
Translational study
The PRISM trial incorporates a strong translational
element that seeks to explore circulating and tissue
based predictive biomarkers of response to immunother-
apy in patients with mRCC. The identification of such
markers represents a research priority. Samples of
plasma, serum and cell-free DNA will be collected in all
consenting patients at baseline, weeks 7, 13 (selected to
coincide with clinic visits) and at disease progression.
Samples will be processed according to strict standard
operating procedures (SOPs) defined within an associated
trial-specific translational manual and all storage kit mate-
rials supplied centrally including barcoded blood tubes. In
select centres, peripheral blood mononuclear cells
(PBMCs) will also be collected from participants at the
same time-points. Where available, an archival formalin-
fixed paraffin embedded tissue block from nephrecto-
mised participants will also be requested.
Fig. 1 PRISM trial schema
Buckley et al. BMC Cancer         (2019) 19:1102 Page 4 of 9
Sample size
The trial will provide a comparison of tolerability be-
tween the modified schedule (Arm A) and standard
schedule (Arm B) and will provide supportive data re-
garding the efficacy of the modified schedule (Arm A) in
relation to historical control data with sunitinib [5]. To
warrant further investigation, the modified schedule
must meet both elements of the primary objective and
show potential in terms of both tolerability and efficacy.
In total, 189 patients (allowing for 5% attrition) will be
recruited in order to adequately power both the toxicity
and efficacy aspects of the study.
Toxicity We expect approximately 40% of participants
to experience a grade 3 or 4 AR within the initial 12
months of treatment when treated with the standard
schedule (Arm B) [18]. To detect a clinically relevant re-
duction to 22% with the modified schedule (Arm A)
(equivalent to a 45% relative reduction; odds ratio
(OR) = 0.423), with 80% power at the two-sided 10% sig-
nificance level, would require 178 participants, allowing
for 5% attrition.
Efficacy Assuming exponential survival, a median
progression-free survival (PFS) with sunitinib of 9
months [5], (equivalent to 39.7% patients progression-
free at 12 months) and targeting a minimum clinically
relevant hazard ratio of 0.73 (corresponding to a median
PFS in the modified Arm A schedule of 12.3 months, or
50.9% progression-free at 12 months) 120 participants
would be required in the modified schedule arm to give
80% power at the one-sided 5% significance level. With
2:1 randomisation, a total of 189 patients will need to be
recruited to allow for 5% attrition. Comparison with his-
torical control data is based on data available at the time
of design from the COMPARZ study [5], however add-
itional unpowered analyses will be considered in light of
the CM214 results now being available.
Consent, eligibility, screening and registration
Potential participants from participating NHS hospitals
in the UK will be provided with verbal and written infor-
mation about the trial and given as long as required to
consider participation. Assenting patients will provide
written informed consent and be registered to the trial
via a central automated 24-h system (provided by
University of Leeds) prior to any trial specific assess-
ments being conducted. Participants can also optionally
consent to take part in HR-QoL and biomarker sub-
studies. Participants retain the right to withdraw at any
time without giving reasons and without their further
treatment being prejudiced.
A full list of inclusion and exclusion criteria can be
found in Table 1. In short, patients aged 18 or over with
advanced or metastatic clear cell RCC, RECIST measur-
able disease and a Karnofsky Performance Status of at
least 70% will be eligible. All IMDC risk-groups, includ-
ing those with favourable-risk disease, are eligible. Pa-
tients will not be eligible if they have undergone prior
systemic anti-cancer treatment or if they have active,
known or suspected autoimmune disease. Eligibility
waivers will not be granted in this trial.
Screening assessments for eligibility will include: Com-
puted tomography (CT) chest, abdomen and pelvis; elec-
trocardiogram (ECG); physical exam and medical
history; full blood count (FBC); urea and electrolytes
(U&Es); liver function tests (LFTs); hepatitis B/C and
human immunodeficiency virus (HIV) tests; calculated
creatinine clearance (CrCI); Karnofsky performance sta-
tus (KPS); IMDC prognostic group classification; where
Fig. 2 Treatment schedule. Frequency and dosing of nivolumab and ipilimumab for both arms of the study are shown
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applicable, pregnancy test. Consenting patients will also
be asked to complete baseline HR-QoL questionnaires.
Those assenting will also give samples of serum and
plasma (and at selected sites only, peripheral blood
mononuclear cells [PBMCs]).
Randomisation
Randomisation will be performed following confirmation of
eligibility (and prior to any trial treatment) via a central auto-
mated 24-h system (provided by University of Leeds) to ei-
ther the modified schedule or the standard schedule on a 2:1
allocation ratio in favour of the modified schedule. A com-
puter–generated minimisation programme incorporating a
random element generated by the independent CTRU Statis-
ticians will be used to ensure treatment groups are well bal-
anced proportionately with respect to: IMDC prognostic
group (favourable/intermediate/poor risk); nephrectomy sta-
tus (nephrectomy/no nephrectomy); and disease type (meta-
static/locally advanced). Irrespective of their randomised
allocation, participants should commence therapy within 14
days of randomisation.
Assessments
A schedule of assessments is provided as supplementary
material in (Additional file 2: Table S2).
During treatment
Due to the difference in treatment schedules, partici-
pants in Arm A (modified schedule) will be assessed
every 2 weeks for the first 12 weeks while those in Arm
Table 1 Eligibility Criteria
Inclusion criteria
Aged 18 years or over
Diagnosed with advanced (not amenable to curative surgery) or
metastatic RCC
Histopathologically confirmed clear cell renal cell cancer (or with a
component of clear cell)
Evidence of measurable disease as per RECIST v1.1
Life expectancy of ≥6 months
Karnofsky Performance Status (KPS) of at least 70%
Required laboratory values within 14 days prior to randomisation:
• WBC≥ 2 × 109/L
• Neutrophils ≥1.5 × 109/L
• Platelets ≥100 × 109/L
• Haemoglobin > 9.0 g/dL
• Serum creatinine ≤1.5 x ULN or calculated creatinine clearance
(CrCl)≥ 40 mL/min (Cockcroft and Gault or Wright formula may be
used according to local practice)
• AST and ALT ≤3 x ULN
• Total Bilirubin ≤1.5 x ULN (except subjects with Gilbert Syndrome,
who can have total bilirubin < 50 μmol/L)
Able to give written informed consent and willing to follow trial
protocol
Women of childbearing potential (WOCBP) must:
• Use appropriate method(s) of contraception for 23 weeks after the
last dose of investigational drug.
• Have a negative serum or urine pregnancy test (minimum
sensitivity 25 IU/L or equivalent units of HCG) before randomisation.
Men who are sexually active with WOCBP must agree to use any
contraceptive method with a failure rate of less than 1% per year.
Men who are sexually active with WOCBP must agree to adhere to
contraception for a period of 31 weeks after the last dose of
investigational product.
Exclusion criteria
Pregnant or breast feeding females.
Prior systemic therapy for RCC (previous participation in adjuvant
studies allowed, providing the patient was on the observation/
placebo arm – this may require unblinding of the patient)
Participants who have undergone any prior systemic anti-cancer treat-
ment, including with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4
antibody, or any other antibody or drug specifically targeting T-cell
co-stimulation or immune checkpoint pathways (previous participa-
tion in adjuvant studies allowed, providing the patient was on the ob-
servation/placebo arm – this may require unblinding of the patient)
Prior malignancy active within the previous 3 years except for locally
curable cancers that have been apparently cured, such as basal or
squamous cell skin cancer, superficial bladder cancer, or carcinoma in
situ of the prostate, cervix, or breast.
Participants who test positive for hepatitis B virus surface antigen
(HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody)
indicating acute or chronic infection.
Participants who test positive for human immunodeficiency virus
(HIV) or have known acquired immunodeficiency syndrome (AIDS).
Untreated brain metastases or brain metastases treated only with
whole brain radiotherapy. (Patients are eligible if previous brain
metastases treated with complete surgical resection, Stereotactic
Brain Radiation Therapy (SBRT), or gamma knife with no subsequent
evidence of progression and asymptomatic).
Active, known or suspected autoimmune disease. (Subjects are
permitted to enrol if they have vitiligo, type I diabetes mellitus,
Table 1 Eligibility Criteria (Continued)
residual hypothyroidism due to autoimmune condition only requiring
hormone replacement, psoriasis not requiring systemic treatment, or
conditions not expected to recur in the absence of an external
trigger).
Patients should be excluded if they have a condition requiring
systemic treatment with either corticosteroids (> 10 mg daily
prednisone or equivalent) or other immunosuppressive medications
within 14 days of study drug administration. (Inhaled or topical
steroids and adrenal replacement doses > 10 mg daily prednisone
equivalents are permitted in the absence of active autoimmune
disease).
Uncontrolled adrenal insufficiency.
Any serious or uncontrolled medical disorder that, in the opinion of
the investigator, may increase the risk associated with study
participation or study drug administration, impair the ability of the
subject to receive protocol therapy, or interfere with the
interpretation of study results.
Palliative radiotherapy less than 14 days prior to first dose of study
drug.
Any history of hypersensitivity to any of the trial medications or
excipients.
Poorly controlled or serious medical or psychiatric illness that, in the
Investigator’s opinion, is likely to interfere with participation and/or
compliance in this clinical trial.
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B (standard schedules) will be assessed every 3 weeks
until week 16. Thereafter, all participants will be
assessed 4-weekly. Each assessment will include: clinical
assessment; adverse event reporting; LFTs; FBC; U&Es;
thyroid function test (TFT); glucose; calcium; amylase;
and cortisol. PROMs will be completed at baseline and
weeks 7, 13, and then 12-weekly until 61 weeks or until
disease progression, whichever is earlier. Assenting par-
ticipants will give samples of serum and plasma (and at
selected sites only, PMBCs) at baseline, weeks 7, 13 and
at disease progression.
The differential reporting between trial arms is not felt
to be a large concern due to: i) the short time lapse
between assessments; ii) there being only 1 week’s differ-
ence in the reporting period between trial arms; iii)
follow-up being 4-weekly for both trial arms for the ma-
jority of the trial; and iv) the primary and key secondary
endpoints being over 12 months. In addition, this differ-
ential follow-up is in favour of the standard schedule
(Arm B) due to more frequent reporting in Arm A
(modified schedule), and is therefore conservative.
All participants will receive radiological assessment ac-
cording to RECIST criteria using contrast enhanced CT
of the chest, abdomen and pelvis every 12 weeks until
disease progression or treatment discontinuation (which-
ever occurs later).
Follow up
The duration of follow-up for individual participants will
vary. Every participant will be followed up with radio-
logical assessments until disease progression or treat-
ment discontinuation, whichever occurs later. Safety
follow-up will continue for 100 days after the last dose of
study drug or death, whichever occurs earlier. A follow-
up visit will be conducted at 30 days post last dose of
trial treatment where assessments will include: clinical
assessment; adverse event reporting; FBC; U&Es; LFTs;
TFTs; and cortisol. Participants will be followed up for
overall survival 12 months post last patient randomised
via centre follow-up.
Outcomes
Primary endpoint
The primary endpoint is the proportion of participants
experiencing a grade 3 or 4 adverse reaction within the
initial 12 months of treatment as graded by CTCAE v5.0.
Key secondary endpoint
Efficacy forms a key secondary endpoint of the study
and will be based on the proportion of participants alive
and progression-free at 12 months. Progression-free sur-
vival will be calculated from the date of randomisation
to first documented evidence of disease progression
(based on RECIST v1.1 criteria) or death. This landmark
survival endpoint provides a pragmatic and timely read-
out of efficacy in this phase II trial and was selected be-
fore the results of the CM214 trial were available. Since
the CM214 trial has now reported, additional explora-
tory analyses will be considered (such as the presenta-
tion of summary statistics for PFS at 12 m by prognostic
group) and will be pre-specified prior to the final ana-
lysis being conducted.
Secondary endpoints
 Safety and toxicity: adverse reactions (ARs), serious
adverse events (SAEs), serious adverse reactions
(SARs) and suspected unexpected serious adverse
reactions (SUSARs) as measured throughout the
trial and graded by common terminology criteria for
adverse events (CTCAE) v5.0;
 Treatment tolerability: the proportion of participants
who experience a treatment delay, the average
number of treatment delays per participant and the
duration of delays as measured over the course of
trial treatment;
 Treatment discontinuation: rates of treatment
discontinuation at any point during trial treatment
and reasons;
 Overall response: the proportion of participants with
partial response or complete response (PR or CR) as
their best response to treatment prior to first-
progression as defined by RECIST v1.1;
 Duration of response: calculated from first
observation of at least PR until disease progression
(as defined by RECIST v1.1) or death;
 Overall survival: calculated from the date of
randomisation to the date of death from any cause;
 Response rate for treatment beyond progression: the
proportion of participants showing a partial or
complete best response (PR or CR) as defined by
RECIST v1.1 when treated beyond progression.
 Health-related Quality of Life: assessed using the
FKSI-19; the EORTC QLQ-C30; study-specific
symptoms and the EQ-5D-5LTM and scored using
the corresponding scoring manuals.
Statistical methods and analysis
Analyses will be conducted following modified
intention-to-treat principles (unless otherwise stated a
priori) meaning participants will be analysed in the
group to which they were randomised regardless of
compliance or cross-over. Participants will be included
in the primary and key secondary analyses provided they
have received at least one dose of trial treatment and
have provided the relevant outcome data.
The primary analysis will examine differences in the
proportion of participants experiencing a grade 3 or 4
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AR within the initial 12 months of treatment between
trial arms using a logistic regression model, adjusting for
minimisation factors (IMDC prognostic group, nephrec-
tomy status, disease type); odds ratios will be presented
alongside corresponding confidence intervals (CI). Pre-
specified sensitivity analyses may be conducted as
appropriate.
Should the primary analysis show a reduction in
toxicity for the modified schedule (Arm A) compared
with the standard schedule (Arm B), the formal key
secondary analysis will be conducted. If the lower
limit of the 90% CI for the proportion of participants
alive and progression-free at 12 months in the modi-
fied schedule only (Arm A) excludes the rate of no
interest based on historical (sunitinib-treated) control
data (39.7%), the modified schedule will be deemed to
have sufficient activity in line with that expected in
the CM214 trial. The trial will provide supportive in-
formation rather than definitive conclusions of super-
iority of the modified arm to sunitinib.
Secondary endpoints will be analysed using summary
statistics alongside confidence intervals where appropri-
ate. All analyses will be fully detailed in a statistical ana-
lysis plan prior to being undertaken.
Trial conduct and oversight
Data will be collected via electronic case report forms
(eCRF). The trial will be conducted in accordance with
the principles of Good Clinical Practice (GCP) and in line
with the relevant Research Governance Framework within
the UK through adherence with CTRU standard operating
procedures (SOPs). An independent Data Monitoring and
Ethics Committee (DMEC) will be established to review
safety data on a regular basis to identify any safety con-
cerns or trends. An independent Trial Steering Committee
(TSC) will periodically review safety data and discuss rec-
ommendations made by the DMEC.
Discussion
Exploration of drug dosing schedules is an important,
yet perhaps over-looked, factor in optimising treatment
for patients with cancer. Alternative scheduling of drugs
may lead to improvement in efficacy and/or tolerability,
as well as in terms of cost-effectiveness. Studies demon-
strating improved tolerability for sunitinib taken on a 2
weeks on, 1 week off basis compared to the standard 4:2
schedule provide a good example of this [19]. Similarly,
enthusiasm for the rapid adoption of immune-oncology
agents into clinical practice must, in parallel, be matched
by careful and robust examination of dosing and sched-
ule, as well as duration of therapy, if efficacy, tolerability,
QoL and cost-effectiveness are to be maximised. The
phase III CM214 study has formally established the effi-
cacy of the combination of nivolumab plus ipilimumab
(using standard 3-weekly ipilimumab) in patients with
mRCC. As oncologists begin to adopt the regimen into
routine clinical practice, the PRISM trial has been de-
signed with the important aim of establishing whether
reduced intensity scheduling of ipilimumab is associated
with reduced toxicity and improved QoL for patients,
without compromising activity. The study has been de-
signed pragmatically, since formal demonstration of
non-inferiority of the experimental schedule to the
current standard in terms of efficacy would not have
been feasible given the required sample size. The results
from our trial may lead to change in clinical practice in
patients with mRCC and have implications for the
scheduling of ipilimumab in other tumour settings when
used in combination with nivolumab. Additionally, as
treatment options continue to burgeon in mRCC,
PRISM meets a research priority by aiming to identify
predictive biomarkers of response to immunotherapy in
this patient population, helping lead the way towards
personalised medicine in this area.
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